[Ip-health] John LaMattian, former head of Pfizer R&D, says industry mergers have harmed R&D efforts | Knowledge Ecology International
james.love at keionline.org
Tue Aug 23 13:14:33 PDT 2011
John L. LaMattina, the former President of Pfizer Global Research and
Development, has just published an article in Nature that looks at the
impact of drug company mergers and increased industry concentration on R&D.
Among his conclusions: the "impact on the R&D of the organizations involved
has been devastating."
NATURE REVIEWS | DRUG DISCOVERY VOLUME 10 | AUGUST 2011 | 559
The impact of mergers on pharmaceutical R&D
John L. LaMattina (former President of Pfizer Global Research and
Mergers and acquisitions in the pharmaceutical industry have substantially
reduced the number of major companies over the past 15 years. The short-term
business rationale for this extensive consolidation might have been
reasonable, but at what cost to research and development productivity?
Concerns about the productivity of pharmaceutical research and development
(R&D) are becoming increasingly common in both the mainstream media and
scientific literature. A range of possible causes have been identified, from
more challenging therapeutic targets to excessive bureaucracy, and various
approaches to address these issues have been put forward (for example, see
REFS 1,2). However, the impact of mergers and acquisitions on R&D
productivity is less well documented, because R&D integrations and cuts are
largely done privately. In this article, it is argued that although mergers
and acquisitions in the pharmaceutical industry might have had a reasonable
short-term business rationale, their impact on the R&D of the organizations
involved has been devastating.
More information about the Ip-health